Literature DB >> 25548393

Plasma Estrogen Levels Are Associated With Severity of Injury and Outcomes After Aneurysmal Subarachnoid Hemorrhage.

Elizabeth A Crago1, Paula R Sherwood2, Catherine Bender2, Jeffrey Balzer3, Dianxu Ren2, Samuel M Poloyac4.   

Abstract

BACKGROUND: Biochemical mediators alter cerebral perfusion and have been implicated in delayed cerebral ischemia (DCI) and poor outcomes after aneurysmal subarachnoid hemorrhage (aSAH). Estrogens (estrone [E1] and estradiol [E2]) are mediators with neuroprotective properties that could play a role in DCI. This study explored associations between plasma estrogen levels and outcomes following aSAH.
METHODS: Plasma samples from 1-4, 4-6, and 7-10 days after hemorrhage from 99 adult aSAH patients were analyzed for estrogen levels using liquid chromatography tandem mass spectrometry. DCI was operationalized as radiographic/ultrasonic evidence of impaired cerebral blood flow accompanied by neurological deterioration. Outcomes were assessed using the Modified Rankin Scale at 3 and 12 months after hemorrhage. Statistical analysis included correlation, regression, and group-based trajectory.
RESULTS: Higher E1 and E2 levels were associated with higher Hunt and Hess grade (E1, p = .01; E2, p = .03), the presence of DCI (E1, p = .02; E2, p = .02), and poor 3-month outcomes (E1, p = .002; E2, p = .002). Trajectory analysis identified distinct populations over time for E1 (61% E1 high) and E2 (68% E2 high). Patients in higher trajectory groups had higher Fisher grades (E1, p = .008; E2, p = .01), more frequent DCI (E1, p = .04; E2, p = .08), and worse 3-month outcomes (E1, p = .01; E2, p = .004) than low groups.
CONCLUSIONS: These results provide the first clinical evidence that plasma E1 and E2 concentrations are associated with severity of injury and outcomes after aSAH.
© The Author(s) 2014.

Entities:  

Keywords:  delayed cerebral ischemia; estrogen; outcomes; subarachnoid hemorrhage

Mesh:

Substances:

Year:  2014        PMID: 25548393      PMCID: PMC4545417          DOI: 10.1177/1099800414561632

Source DB:  PubMed          Journal:  Biol Res Nurs        ISSN: 1099-8004            Impact factor:   2.522


  40 in total

Review 1.  Estrogen and stroke: a balanced analysis.

Authors:  Patricia D Hurn; Lawrence M Brass
Journal:  Stroke       Date:  2003-02       Impact factor: 7.914

2.  Age- and ethnic-specific sex differences in stroke risk.

Authors:  Shawnita Sealy-Jefferson; Jeffrey J Wing; Brisa N Sánchez; Devin L Brown; William J Meurer; Melinda A Smith; Lewis B Morgenstern; Lynda D Lisabeth
Journal:  Gend Med       Date:  2012-03-23

3.  Impact of aromatase genetic variation on hormone levels and global outcome after severe TBI.

Authors:  Julie A Garringer; Christian Niyonkuru; Emily H McCullough; Tammy Loucks; C Edward Dixon; Yvette P Conley; Sarah Berga; Amy K Wagner
Journal:  J Neurotrauma       Date:  2013-08-15       Impact factor: 5.269

Review 4.  Transition of research focus from vasospasm to early brain injury after subarachnoid hemorrhage.

Authors:  Basak Caner; Jack Hou; Orhan Altay; Mutsumi Fujii; John H Zhang
Journal:  J Neurochem       Date:  2012-11       Impact factor: 5.372

5.  Estradiol levels predict short-term adverse health outcomes in postmenopausal acute stroke women.

Authors:  T Pappa; K Vemmos; E Mantzou; P Savvari; K Stamatelopoulos; M Alevizaki
Journal:  Eur J Neurol       Date:  2012-04-17       Impact factor: 6.089

Review 6.  Endothelin receptor antagonists for aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis update.

Authors:  Mervyn D I Vergouwen; Ale Algra; Gabriel J E Rinkel
Journal:  Stroke       Date:  2012-08-07       Impact factor: 7.914

Review 7.  The importance of early brain injury after subarachnoid hemorrhage.

Authors:  Fatima A Sehba; Jack Hou; Ryszard M Pluta; John H Zhang
Journal:  Prog Neurobiol       Date:  2012-03-10       Impact factor: 11.685

Review 8.  Delayed cerebral ischemia after subarachnoid hemorrhage: a systematic review of clinical, laboratory, and radiological predictors.

Authors:  Nicolien K de Rooij; Gabriel J E Rinkel; Jan Willem Dankbaar; Catharina J M Frijns
Journal:  Stroke       Date:  2012-12-18       Impact factor: 7.914

9.  Liquid chromatography-tandem mass spectrometry assay for simultaneous measurement of estradiol and estrone in human plasma.

Authors:  Robert E Nelson; Stefan K Grebe; Dennis J OKane; Ravinder J Singh
Journal:  Clin Chem       Date:  2003-12-04       Impact factor: 8.327

Review 10.  Endothelin-receptor antagonists for aneurysmal subarachnoid hemorrhage: an updated meta-analysis of randomized controlled trials.

Authors:  Junpeng Ma; Siqing Huang; Lu Ma; Yi Liu; Hao Li; Chao You
Journal:  Crit Care       Date:  2012-10-18       Impact factor: 9.097

View more
  4 in total

1.  Systemic Estrone Production and Injury-Induced Sex Hormone Steroidogenesis after Severe Traumatic Brain Injury: A Prognostic Indicator of Traumatic Brain Injury-Related Mortality.

Authors:  Milap V Rakholia; Raj G Kumar; Byung-Mo Oh; Prerna R Ranganathan; Sarah L Berga; Patrick M Kochanek; Amy K Wagner
Journal:  J Neurotrauma       Date:  2018-08-24       Impact factor: 5.269

2.  Sex-related differences of invasive therapy in patients with aneurysmal subarachnoid hemorrhage.

Authors:  S Y Bögli; D Utebay; N Smits; L P Westphal; L Hirsbrunner; S Unseld; E Keller; G Brandi
Journal:  Acta Neurochir (Wien)       Date:  2022-08-19       Impact factor: 2.816

Review 3.  Sex Differences in the Formation of Intracranial Aneurysms and Incidence and Outcome of Subarachnoid Hemorrhage: Review of Experimental and Human Studies.

Authors:  Nefize Turan; Robert Allen-James Heider; Dobromira Zaharieva; Faiz U Ahmad; Daniel L Barrow; Gustavo Pradilla
Journal:  Transl Stroke Res       Date:  2015-11-16       Impact factor: 6.829

4.  A sensitive and robust UPLC-MS/MS method for quantitation of estrogens and progestogens in human serum.

Authors:  Junmei Zhang; Chenxiao Tang; Patrick J Oberly; Margaret B Minnigh; Sharon L Achilles; Samuel M Poloyac
Journal:  Contraception       Date:  2019-01-24       Impact factor: 3.375

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.